Home/Pipeline/SUJANU® Combination Tablets

SUJANU® Combination Tablets

Type 2 Diabetes

ApprovedCommercial

Key Facts

Indication

Type 2 Diabetes

Phase

Approved

Status

Commercial

Company

Kotobuki Pharmaceutical

About Kotobuki Pharmaceutical

A Japanese pharmaceutical company focused on manufacturing and developing small molecule drugs in gastroenterology, oncology, and neurology, with expertise in formulation development.

View full company profile

Therapeutic Areas

Oncology Gastroenterology Neurology Metabolic Disease Pain

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active